Do new SARS-Cov-2 variants induces cross-reactive immune responses?
Channel: Immunopaedia
Date: 2021-04-09

Does immunity induced by the B1.1.135 (501Y.V2) variant offer cross-reactive immune responses against other variants such as the 501Y.V2 (P2) variant first detected in Brazil? A recent article by Moyo-Gwete et al., 2021 demonstrated that 501Y.V2 elicits robust neutralizing antibody responses against both the original variant and 501Y.V3 (P.1), which indicates high levels of cross-reactivity. Our data indicate that vaccines built on the spike protein of 501Y.V2 may be promising candidates for the elicitation of cross-reactive neutralizing antibody responses to SARS-CoV-2.